孟鲁斯特辅助治疗小儿中重度变应性鼻炎疗效观察

Therapeutic efficacy of montelukast on children with moderate and severe allergic rhinitis

目的观察孟鲁斯特辅助治疗小儿中重度变应性鼻炎的临床效果。方法采用随机分组对门诊就诊的96例中重度变应性鼻炎患儿分为两组。对照组46例,予氯雷他定口服及布地奈德鼻喷雾剂喷鼻。治疗组50例,在对照组治疗的基础上,加用孟鲁斯特口服。疗程均为8周,比较两组治疗前后症状、体征评分,计算有效率。结果治疗组显效率明显高于对照组,差异有统计学意义(P<0.05)。结论孟鲁斯特辅助治疗小儿中重度变应性鼻炎安全有效,值得推广。

Objective To assess the efficacy of montelukast on moderate and severe allergic rhinitis（AR）.Methods 96 children with moderate and severe AR in clinic from Aug 2010 to Jan 2011 were randomly divided into two groups： objective group（n=50） and control group（n=46）.All the children of two groups took loratadine and Budesonide Nasal Spray,while those of objective group additionally took montelukast;for eight weeks.Scores of symptom and sign of rhinitis were recorded and effective rate of each group was calculated.Results The significant efficiency rate of objective group was higher than that of the control group;A significant difference existed between the two groups（P 0.05）.Conclusion The montelukast is effective and safe for the treatment of moderate and severe AR.It is worthy of being widely used.